As bstract. To assess the relative contributions of encainide and its putatively active metabolites, O-demethyl encainide (ODE) and 3 methoxy-O-demethyl encainide (3MODE), to the drug's pharmacologic effects, we compared intravenous infusions and sustained oral therapy in two phenotypically distinct groups of patients, extensive and poor metabolizers ofencainide. Unlike poor metabolizers, extensive metabolizers had appreciable quantities of both metabolites detectable in plasma and had fourfold shorter elimination half-lives for encainide. By quantitating electrocardiogram intervals, arrhythmia frequency, and plasma concentrations, we found that, in poor metabolizers, arrhythmia suppression and ventricular complex (QRS) prolongation were correlated positively with encainide concentrations (r . 0.570, P < 0.014). In these two subjects, antiarrhythmic concentrations of encainide (>265 ng/ml) were at least fivefold higher than those sustained in the six extensive metabolizers during steady state oral therapy. In extensive metabolizers, encainide concentrations were uncorrelated with effects. Arrhythmia suppression and QRS prolongation in extensive metabolizers correlated best with ODE (r . 0.816, P < 0.001); QTc change correlated positively
Introduction
Encainide is a benzanilide derivative chemically identified as 4-methoxy-2'-(2-I -methyl-2-piperidyl ethyl) benzanilide, which has been investigated extensively in recent years as a new antiarrhythmic agent. Studies in man have shown it is highly effective in suppressing both high frequency ventricular ectopic depolarizations (VED)' (1) and more life-threatening arrhythmias, such as ventricular tachycardia (VT) (2, 3) . In most series, 80-90% of such patients have responded satisfactorily to encainide therapy without limiting side effects (1) (2) (3) (4) (5) (6) . In association with its antiarrhythmic action, encainide administration also is marked by the production of characteristic changes in the electrocardiogram (ECG), including prolongation of the QRS and PR durations and, to a lesser extent, of the QT interval.
In an earlier series (1) of eleven patients treated in a placebocontrolled double-blind crossover protocol at our own institution, the single patient whose arrhythmia failed to respond had 20-100-fold higher steady state plasma concentrations of encainide than the mean for the other 10 responding patients. This patient also showed minimal ECG changes, a threefold longer elimination half-life for encainide and no detectable plasma metabolite concentrations. These observations, coupled with disparities noted in electrophysiologic effects dependent on the mode and timing of drug administration (6, 7) , have strongly suggested the role of one or more active metabolites in the expression of encainide effects.
The main features of encainide metabolism have been outlined from animal studies and preliminary work in man (8, 9) , as shown schematically in Fig. 1 A and B. Encainide taken orally is virtually completely absorbed from the gastrointestinal tract in all patients, but then undergoes a polymorphic pattern of "first-pass" metabolism in the liver. In about 90% of patients (10) , there is extensive hepatic demethylation ofthe parent molecule ( Fig. 1 A, site "A") to form O-demethyl encainide (ODE). These patients usually also have an accompanying metabolite detectable in their plasma, 3-methoxy-0-demethyl encainide (3MODE), which appears to be formed by addition ofa methoxy group to ODE ( Fig. 1 A, site "B"), perhaps via a catechol intermediate. Members of this phenotypic group of "extensive metabolizers" have systemic bioavailability of 25-45%; their elimination half-lives for encainide range from 1 to 4 h (8, 9) .
About 10% of patients have a qualitatively different pattern of drug disposition, with little first-pass metabolism, much greater bioavailability, and much longer elimination half-lives (8-36 h) . ODE is either undetected or found in greatly reduced quantities, and we have not seen detectable quantities of 3MODE in their plasma. These "poor" metabolizers sometimes accumulate measurable quantities of another metabolite, N-demethyl encainide (NDE), formed by removal of a methyl group (Fig.  1 A, site "C").
In animal studies, all three metabolites are active. ODE has electrophysiologic and antiarrhythmic activity of greater potency than encainide (1 1, 12, 13), and 3MODE has similar actions with about the same potency as the parent drug (1 1, 12 On the day of encainide infusions, patients remained supine for at least I h before continuous ECG recording of a I -h base-line arrhythmia frequency began to insure that ambient arrhythmia did not disappear or decline markedly as a result of change in posture. Blood samples were drawn immediately before the 20 min infusion began, every 5 min during the infusion, and 0.25, 0.5, 1, 1.5, 2.5, 4, 6, 9, and 20 h afterwards.
All infusions were begun between 9 a.m. and 2 p.m. The patients remained supine until either VED frequency had returned to 10% of base line or until 2 h after completion of the infusion (whichever was longer). Thereafter, they were allowed to ambulate freely.
Sustained Base-line arrhythmia frequencies were determined as follows: for comparison with the infusions, supine frequency was measured during the 60-min period of observation immediately before drug was administered. Base line for sustained oral therapy was measured during a 4-h ambulatory period of observation at the end of the oral withdrawal study (at least 24 h after the last encainide dose in every instance and greater than 72 h for the two slow metabolizers). Defined in this wayj the means for both base-line values varied by <10% from 12-h ambulatory arrhythmia counts performed on the same patients when they were free of antiarrhythmic therapy. Data analysis using the 12-h counts as base line for both the acute and sustained oral studies produced qualitatively similar results to those reported in this paper.
Plasma concentrations and pharmacokinetics
Plasma concentrations of encainide, ODE, 3MODE, and NDE were assayed by using a high-pressure liquid chromatography technique modified to utilize an internal standard (13, 14) . For 
Arrhythmia frequency
The taped ECG were analyzed by a computer operator who was unaware of the timing of encainide therapy and used a PDP 11/60 laboratory mini computer (Digital Equipment Corp., Maynard, MA) and a previously described and verified arrhythmia analysis program (16) . For closely timed observation periods during the infusions, computer reports were verified by hand count. The time period chosen for reporting arrhythmia count was a 30-min interval which evenly bracketed the time of blood sampling; when sampling intervals were close enough that this definition would result in overlap, observation periods were reduced to the minimum time necessary to avoid overlap.
Data analysis
Regression. Simple linear regression lines were obtained by the leastsquares fit technique. Strength of association in multiple linear regression (17, 18) was assessed by inspecting the normalized regression coefficient, the additive contribution to the R-value of the regression equation, and the partial correlation coefficients derived according to standard methodology (19) by using a stepwise program (CLINFO) (20) .
Hysteresis. Time-ordered, concentration-effect (hysteresis) plots (21-23) of data collected during infusions were tested for significance by comparison ofthe area under the curves oftheir ascending and descending limbs by using t test for unpaired data. A difference between the two areas would indicate a different relationship between concentration and effect that was a function of time: possible explanations for counterclockwise hysteresis would include formation of active metabolites, delayed onset and/or termination of effect of drug at its active site, or the importance of drug concentration in a compartment other than plasma (23, 24) . To allow forthe possibility that the hysteresis noted for encainideeffect relationships was due to delayed tissue penetration, data sometimes were selected from only the descending limb of the hysteresis plot and then combined with the oral data for further regression analysis. These data were termed "postdistribution" data.
Statistics. A probability of <0.05 was sufficient to reject the null hypothesis; when appropriate, the Bonferroni inequality (25) was utilized to adjust the P value for multiple comparisons. Differences of variables from base line were tested for overall significance by analysis of variance (ANOVA). If ANOVA rejected the null hypothesis of no difference, values from each time point were tested against the base-line values by using a modified t test for paired data with the ANOVA mean square error used as the standard error (25) . Because ofnonnormal distribution, the statistical test used for VED suppression was Wilcoxon signed ranks. For regressions, linear transformation of the VED data to the logistic function was done by using the formula: logit = In (y/100 -y). Values for normalized suppression of VED >99.5% and <0.5% were assigned values of 99.5 and 0.5 in order to permit inclusion of such extreme values in the logistic function.
Results

Plasma concentrations and pharmacokinetics
All six extensive metabolizers of encainide had, in addition to encainide itself, both ODE and 3MODE detectable in their plasma on oral therapy. Following intravenous infusions, all had measurable encainide and ODE, but only four of the six had detectable 3MODE. The mean log-concentration vs. time plots for this group of patients after infusion and during withdrawal from sustained oral therapy are shown in Fig. 2 A and  B . Encainide log-concentration vs. time plots for oral therapy in subjects 7 and 8, the two poor metabolizers, are shown for comparison in Fig. 3 .
Encainide elimination half-lives for the eight subjects are summarized in Table I . There were no marked differences in the encainide elimination half-lives for any subjects between acute and chronic therapy. Because of his extremely long calculated TI/2, subject 7 probably was not at steady state when studied on sustained oral therapy.
Antiarrhythmic and electrocardiographic effects
Oral dosages that resulted in .90% VED suppression are listed in Table I . Poor (Table II) . Data for each subject also were subjected to regression analysis with similar results (data available upon request).
Overall, the strongest correlation between any one substance and either VED suppression or QRS effect was demonstrated for ODE. However, positive correlations with VED and QRS effects also were noted for encainide and for 3MODE. To characterize further the effects of each pharmacologic substance, PR in subjects 6, 7, and 8; subject 5 developed atrial fibrillation during oral encainide therapy and thus neither PR nor QTc could be measured. Maximum levels ofeffects on VT frequency, VED frequency, and QRS duration are listed for each subject in Table I . The mean maximum effects on PR and QTc durations for the available subjects were 34.4 and 17.7%, respectively. Concentration-response curve when metabolites were undetectable Subject 7 after intravenous therapy and subject 8 after an acute oral dose had no metabolites detectable in their plasma. During sustained oral therapy, subject 7 accumulated small quantities of ODE and NDE, and subject 8 accumulated very small quantities of ODE. We selected for study only those postdistribution time points at which either no metabolites were detectable or (for subject 7) at which the level of ODE was below the limits of sensitivity of the assay (< 15 ng/ml). Concentration-response curves showed significant (P < 0.001, r = 0.891, 0.774) linear relationships between QRS width and plasma encainide (Fig.  4 A and B) , and less close but still significant (P < 0.014, r = 0.760, 0.570) relationships between antiarrhythmic effect (expressed as logit VED) and plasma encainide (data not shown). The plasma concentrations of encainide in these two patients associated with >90% arrhythmia suppression (>265 ng/ml) when metabolites were undetectable were at least fivefold higher Hysteresis analysis. Fig. 5 A-C illustrates the percent reduction in VED plotted against the concentration of encainide, ODE, and 3MODE obtained during the infusion studies. For encainide, there was significant counterclockwise hysteresis (that is, less antiarrhythmic effect associated with a given plasma concentration early in the infusion than later on). For 3MODE, the reverse was true: there was clockwise hysteresis (that is, a greater effect associated with a given plasma concentration early in the infusion than later on). For the ODE metabolite, no significant hysteresis was detected. Similar relationships between QRS width and the encainide, ODE, and 3MODE plasma concentrations were observed.
Multiple linear regression. When either all data or only postdistribution data derived from infusion and oral therapy were subjected to multiple linear regression, the strong association of VED suppression and QRS effects with ODE concentrations persisted, while partial correlation coefficients for 3MODE and encainide fell below statistically significant levels (Table II) . Similar relationships were seen for PR effect.
QTc effects Regression analysis of QTc data for extensive metabolizers showed significant positive correlations for both 3MODE and ODE which persisted when partial correlation coefficients were calculated (Table II) . Hysteresis analysis showed a marked counterclockwise loop for encainide; there was a trend for counterclockwise hysteresis for ODE and also for clockwise hysteresis for 3MODE.
Relationship between antiarrhythmic and electrocardiographic effects Changes over time in VED frequency and QRS width occurred virtually simultaneously among the extensive metabolizers; there was no apparent hysteresis. A close linear relationship was found between VED suppression, expressed as the logit function, and QRS prolongation (r = 0.907, P < 0.001 for mean data). The slopes of the linear regression lines for logit VED suppression vs. QRS in the poor metabolizers did not differ significantly from that calculated for the extensive metabolizers, although there was a trend for the poor metabolizers to have proportionately more VED suppression for a given level of QRS effect (Fig. 6 ).
Discussion
Other antiarrhythmic agents have been shown to have actions mediated by active metabolites, including lidocaine (26), procainamide (27) , and quinidine (22) . In the case of encainide, this was a possibility first suspected in early studies based on a disparity between the pharmacokinetic characteristics of the parent drug and the pharmacodynamic responses observed in the study group of patients (1). The present study amplifies those disparities and provides strong support for the hypothesis that, among extensive metabolizers, a metabolite of encainide, probably ODE, is primarily responsible for the drug effects observed. In addition, evidence is presented for the first time that the parent drug, encainide, has antiarrhythmic and electrocardiographic activity of its own in man at high plasma concentrations (>265 ng/ml). Also, the data suggest that arrhythmia suppression parallels QRS prolongation and that the relationship between these two clinically observable effects is at least qualitatively similar in patients belonging to both the extensive and poor metabolizer groups.
That ODE is the principal mediator of encainide effects in extensive metabolizers is suggested by (a) the absence of significant time-ordered hysteresis loops of drug effects for this metabolite in the infusion studies, and by (b) the consistency of its correlation with drug effects in the multiple regression analyses. These consistent relationships between drug effects and ODE plasma concentrations in the extensive metabolizers were not found for either encainide or 3MODE plasma concentrations. Furthermore, the opposite directions oftime-ordered VED suppression ENCAINIDE (ngtnl) ODE(WMnl) Figure 5 . Hysteresis plots of percent suppression of VED against plasma concentrations of (A) encainide, P < 0.05, (B) ODE, P > 0.3, and (C) 3MODE, P < 0.1, for the infusion studies in extensive metabolizer subjects 1-6. The points are connected in the time order in which they were obtained. In summary, our data point toward another explanation of the observed correlation in previous studies between plasma encainide and pharmacologic effect-that both these variables were related to each other through an intervening variable, namely plasma ODE.
In this, as in previous studies (1) (2) (3) (4) 29) , the antiarrhythmic effect of encainide paralleled the characteristic ECG effects, and no marked differences were found between the two patient groups. Two practical conclusions about encainide use can be drawn from these data: (a) Antiarrhythmic effects are a saturable function of encainide (or ODE) plasma concentration; ECG effects are linear functions which continue to increase past the plasma levels at which the antiarrhythmic effect has been maximized. (b) Expectation of antiarrhythmic effect can be related to the extent of QRS change, regardless of a patient's metabolic phenotype.
The QTc data should be regarded cautiously; after this study was completed, it was reported that marked temporal changes in QTc interval occurred following oral and intravenous administration of placebo (22) . We did not use placebos; it is possible that some ofthe variation in QTc observed in this study was a temporal phenomenon. Yet, the data obtained by multiple regression and by examining hysteresis plots suggest that each metabolite contributes independently to QTc change.
Genetic variation in drug disposition has become recognized as an important variable in determining the pattern of response to an increasing number of pharmacologic agents (30) (31) (32) , with implications both for therapeutic response and for the development of unwanted adverse effects. Investigations by us have linked encainide disposition to the phenotypic pattern of oxidation of the antihypertensive drug, debrisoquine (10) . Debrisoquine disposition, in turn, has been linked to polymorphic oxidative patterns for other substances, such as sparteine (33), phenytoin (34) , phenacetin (35) , phenformin (36) , nortryptyline (37) , and several beta blockers (38, 39) .
What implications should an understanding of the distinct oxidative phenotypes for encainide have for drug administration in man? Our data suggest that the antiarrhythmic activity of unmetabolized encainide appears only at concentrations (>265 ng/ml) well above those sustained on oral therapy in most patients (1, 9), i.e., the >90% who fall in the extensive metabolizer group. Such concentrations might be achieved transiently in extensive metabolizers either by rapid intravenous infusion or at the peak achieved immediately following oral ingestion, but then would fall off rapidly as the parent drug distributes to tissues and is oxidized to ODE. Thus, unchanged encainide would be expected to contribute substantially to the effects of orally administered drug only in poor metabolizers.
In both phenotypic groups, there is an active compound in plasma with a relatively long elimination t1/2: ODE in the extensive metabolizers (>6 h) (9) and encainide in the poor metabolizers (>8 h). In all patients, the time course of pharmacologic effect will be considerably longer than the short 1-4-h half-life described originally for encainide in extensive metabolizers. Schedules for drug administration ought to reflect these pharmacodynamic considerations. The evidence in this study suggesting a central role for the metabolite ODE in the mediation of encainide effects in most patients is, of course, inferential. Although there is strong evidence in animal models that ODE is electrophysiologically active (1 1, 12, 40, 41) and antiarrhythmic (13) , direct demonstration in man would entail the administration of ODE, which is not yet available for use in humans. Such studies would be analogous to the development of N-acetylprocainamide, a procainamide metabolite, as a human antiarrhythmic agent in its own right (27) . In broader terms, these demonstrations in clinical investigations of polymorphic patterns of metabolism and of the importance of metabolites in the mediation of drug effects have important implications for methodological approaches in future drug development. Such approaches might include the earlier identification of subjects with less typical metabolic phenotypes for pharmacokinetic and dynamic studies and also the earlier characterization of pharmacologic effects of metabolites.
